RecruitingPhase 3NCT03150693
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Sponsor: Alliance for Clinical Trials in Oncology
Houston, TX · Lubbock, TX · +453 more sites
Leukemia clinical trials in Houston, TX
96 recruiting leukemia studies with a site in Houston, TX.
RecruitingPhase 2NCT06317662
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Sponsor: National Cancer Institute (NCI)
Austin, TX · Corpus Christi, TX · Dallas, TX · +112 more sites
RecruitingPhase 2NCT05554393
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Houston, TX · +173 more sites
RecruitingPhase 1NCT06846606
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Sponsor: Auron Therapeutics, Inc.
Houston, TX · +8 more sites
RecruitingPhase 1 / Phase 2NCT07109219
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Sponsor: AstraZeneca
Houston, TX · +5 more sites
RecruitingPhase 1NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Sponsor: Ascentage Pharma Group Inc.
Houston, TX · +4 more sites
RecruitingPhase 2NCT06317649
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Houston, TX · +223 more sites
RecruitingPhase 1NCT02390635
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT06137118
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Sponsor: AstraZeneca
Houston, TX · +11 more sites
RecruitingPhase 2NCT06236724
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 3NCT07007312
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Sponsor: Kura Oncology, Inc.
Austin, TX · Dallas, TX · Houston, TX · +41 more sites
RecruitingPhase 2NCT07269470
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT04065399
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Sponsor: Syndax Pharmaceuticals
Houston, TX · +21 more sites
RecruitingPhase 1NCT05010772
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT07128381
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 2NCT00501826
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 2NCT07060001
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
Sponsor: The Methodist Hospital Research Institute
Houston, TX
RecruitingPhase 2NCT00801489
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase not listedNCT00816114
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1NCT03896269
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT04140487
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Sponsor: Hoffmann-La Roche
Houston, TX · +4 more sites
RecruitingPhase 2NCT06811233
Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 2NCT03586609
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT06235801
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 2 / Phase 3NCT07581002
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Sponsor: AbbVie
Houston, TX · +5 more sites
RecruitingPhase 2NCT06817720
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Sponsor: Orca Biosystems, Inc.
Houston, TX · +11 more sites
RecruitingPhase 2NCT06514794
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Sponsor: Allotera Therapeutics
Houston, TX · San Antonio, TX · +14 more sites
RecruitingPhase 2NCT03629171
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT04925479
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia
Sponsor: Novartis Pharmaceuticals
Houston, TX · +7 more sites
RecruitingPhase 1NCT06401603
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT06548230
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 3NCT06852222
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Sponsor: Janssen Research & Development, LLC
Dallas, TX · Houston, TX · +56 more sites
RecruitingPhase 3NCT07211958
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Sponsor: Syndax Pharmaceuticals
Houston, TX · +5 more sites
RecruitingPhase 1NCT03630991
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 3NCT04293562
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Sponsor: Children's Oncology Group
Austin, TX · Corpus Christi, TX · Dallas, TX · +183 more sites
RecruitingPhase 1NCT06786533
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
Sponsor: Hemogenyx Pharmaceuticals LLC
Houston, TX
RecruitingPhase 1NCT06345027
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Sponsor: Baylor College of Medicine
Houston, TX
RecruitingPhase 2NCT06824168
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Sponsor: Daiichi Sankyo
Houston, TX · +13 more sites
RecruitingPhase 2NCT04996875
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Sponsor: Cogent Biosciences, Inc.
Houston, TX · +13 more sites
RecruitingPhase 1 / Phase 2NCT03471260
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Sponsor: M.D. Anderson Cancer Center
Houston, TX · +3 more sites
RecruitingPhase 2NCT03683433
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 2NCT04216524
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1NCT04972942
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Sponsor: New York Medical College
Houston, TX · +15 more sites
RecruitingPhase 2NCT06566742
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Sponsor: M.D. Anderson Cancer Center
Houston, TX · +1 more sites
RecruitingPhase 2NCT04169737
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT05010122
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1NCT05010564
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)
Sponsor: Baylor College of Medicine
Houston, TX
RecruitingPhase 2 / Phase 3NCT03013998
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Sponsor: Beat AML, LLC
Dallas, TX · Houston, TX · +29 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.